Podcasts about ocular therapeutix

Drs. Akshay Thomas and Priya Vakharia join to preview the April 2025 edition of Retinal Physician, focusing on current and future therapies for neovascular AMD.Relevant Financial Disclosures: Dr. Sridhar has consulted for Genentech, Regeneron, and Eyepoint. Dr. Vakharia has consulted for Regeneron, Ocular Therapeutix, and Eyepoint.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

In this edition of the OIS Podcast, a powerhouse panel of investment, banking, and biotech leaders offers unfiltered insights on the current and future state of the ophthalmic industry. Featuring Andrew Gitkin (Leerink Partners), Cameron Taylor (Bank of America), Susan Orr, PhD (Claris Bio), and Anupam Dalal, MD (Acuta Capital), and Dr. Pravin Dugel, Chairman and CEO of Ocular Therapeutix, this session explores how macroeconomic and political shifts—such as RFK Jr.'s FDA rhetoric and rising interest rates—are influencing capital markets, regulatory confidence, and biotech strategy. With humor, candor, and deep expertise, the panel discusses: 

Welcome to a special episode of the "Being an Engineer" podcast, marking the beginning of our new "Open to Work" series. Part of the stated purpose of the BAE podcast is to “connect with the companies, technologies, people, resources, and opportunities featured on our show.” In alignment with that purpose, my goal for this open to work series is to provide a platform for engineers who are currently seeking new opportunities, sharing their experiences and insights in an open and candid manner to connect these talented professionals with our community of listeners who may be able to offer support or job leadsOur first guest in this series is Erica Kahn, she is here to share her journey, discuss the challenges of being unexpectedly out of work, and provide valuable insights that can benefit engineers who may find themselves in a similar situation.We are honored to have her kick off this important series. Through her candid discussion, we hope to provide not only a connection for Erica but also a source of inspiration and practical advice for our listeners.Main Topics:Erica's work developing hydrogel technologies for eyecareCreativity in engineeringCoping with job lossLeveraging her networkCareer development after being laid offAbout the guest: Erica Kahn, is a highly accomplished biomedical engineer with a wealth of experience in the medical device industry. Erica previously worked for Ocular Therapeutix, where she made significant contributions to the development of innovative hydrogel technologies for ocular applications. Links:Erica Kahn - LinkedInEmail - Ekahn92@gmail.com About Being An Engineer The Being An Engineer podcast is a repository for industry knowledge and a tool through which engineers learn about and connect with relevant companies, technologies, people resources, and opportunities. We feature successful mechanical engineers and interview engineers who are passionate about their work and who made a great impact on the engineering community. The Being An Engineer podcast is brought to you by Pipeline Design & Engineering. Pipeline partners with medical & other device engineering teams who need turnkey equipment such as cycle test machines, custom test fixtures, automation equipment, assembly jigs, inspection stations and more. You can find us on the web at www.teampipeline.us

About Dr. Bollinger Dr. Bollinger is a board-certified optometrist and a Fellow of the American Academy ofOptometry which demonstrates her commitment to excellence and lifelong learning inher profession. She has participated in advisory board meetings & also as a KeyOpinion Leader for companies such as Alcon, Ocular Therapeutix, Novartis, ScienceBased Health, Viatris, and TearScience. She enjoys educating which allows herto share her passion and expertise on dry eye and ocular surgery with other eye careprofessionals and the public. She earned her undergraduate degree in Biology at MiamiUniversity in Ohio and her Doctor of Optometry degree at Ohio State University. Sheserved as an adjunct clinical professor at Ohio State University from 2006-2012. Shehas participated as a clinical investigator in several FDA pharmaceutical and surgicalstudies for dry eye disease, presbyopia, topical steroids, intraocular lenses, andDemodex blepharitis. Her primary career goal is to help patients achieve optimal visionand eye health through personalized and evidence-based care.As an optometrist with 30+ years of experience, she strives to provide exceptional eyecare to patients with various ocular conditions and needs. She has extensiveexperience in perioperative surgical eye care, managing thousands of cases ofrefractive, cataract, and cornea surgeries throughout her career. Dr. Bollinger is alsoskilled in medical eye care, treating patients with glaucoma, diabetes, maculardegeneration, and dry eyes. Helping patients with ocular surface disease, including dryeye, meibomian gland disease, & blepharitis is her primary passion. She currently sees patients at Jacksoneye in Lake Villa, Illinois.

Quick episode summary John A. Hovanesian, MD, FACS, and Jim Mazzo sit down with guests Eric D. Donnenfeld, MD, Calvin C. Roberts, MD, Mark L. Baum and Jeannette Bankes to discuss private equity, industry breakthroughs and more. Welcome to the Eyeluminaries podcast :00 Review of episode 20 1:16 Intro of Eric D. Donnenfeld, MD 2:06 Understanding the role of private equity: where does it stand and where is it going? 4:22 Do you see a relief in interest rates and the pace picking up for private equity in the years ahead? 7:19 What are the technologies that you are most excited about? 8:17 What are the things to watch out for? 11:08 Do you have an interesting James Worthy story? 13:34 Intro of Calvin C. Roberts, MD 15:21 Transplanting eyes and Advanced Research Project Agency for Health (ARPA-H) 15:48 How does a chief medical officer work within a company? 18:56 How is what ARPA-H doing different than simply transplanting an eye? 20:42 Intro of Mark L. Baum 26:06 What does the rebranding of the company mean? 27:00 Pharmaceutical names: VEVYE 28:22 How will you market VEVYE in the US? 29:48 Fortisite 31:59 What is the future of the company? 32:47 What do you think of Dr. Wiley Chambers' retirement? 34:09 Intro of Jeannette Bankes 36:51 Describe your last five years in the ophthalmic space: the good, the bad, the ugly 39:16 ·       If you could change anything in the ophthalmic industry, what would it be? 42:53 ·       How excited are you about robotics? 44:06 ·       Tell us about your promotion 44:52 ·       How can we develop a more diverse leadership in ophthalmology? 45:31 Preview of episode 22 48:01 Feedback, questions and guest suggestions at eyeluminaries@healio.com 48:18   Jeannette Bankes is the president and general manager of global surgical franchises for Alcon. Mark L. Baum is the founder, chairman of the board and chief executive officer of Harrow. Eric D. Donnenfeld, MD, is a cornea, laser cataract and refractive surgeon for OCLI Vision. John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA. Calvin C. Roberts, MD, is a program manager for health science futures at ARPA-H. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Bankes is the president and general manager of global surgical franchises for Alcon. Baum is the founder, chairman of the board and chief executive officer of Harrow. Donnenfeld reports consulting widely across the ophthalmic industry with relevant disclosures in this episode as a consultant with Alcon, Bausch + Lomb, LensGen, Ocular Therapeutix and Omeros. Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Thompson is the director of refractive surgery at Vance Thompson Vision. Roberts is program manager for health science futures at ARPA-H.

We discuss the use of a novel drug (tyrosine kinase inhibitor) and novel delivery system (hydrogel) for the treatment of neovascular AMD with Dr. Peter Kaiser of the Cleveland Clinic.

Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, chat with Richard L. Lindstrom, MD, about the latest news and trends, as well as his career and his advice for residents and entrepreneurs in the field of ophthalmology.        Welcome to the Eyeluminaries podcast :00        OTF Meeting 01:41        Gezundheit award – Iheezo (chloroprocaine hydrochloride ophthalmic gel) 4:04        Name stolen from a birthday party magician award – Vabysmo (faricimab-svoa) 4:42        The incomplete sentence award – Iyuzeh (latanoprost ophthalmic solution) 5:21        Big improvement on the generic name award – Zimura (avacincaptad pegol) 6:24        Best of the year award – Pegcetacoplan 6:49        Near miss award – Beovu (brolucizumab) 8:08        Awful award – Byooviz (ranibizumab-nuna) 8:45        Guest welcome 9:40        Richard L. Lindstrom, MD, introduction 10:31        FDA grants fast track designation for retinitis pigmentosa treatment 10:36        EyeArt AI system approved in EU for detecting AMD, glaucomatous optic nerve damage 13:14        Amazon launches discount prescription drug service 17:46        Interview with Lindstrom 21:42        What is the biggest innovation in ophthalmology in your career? 22:40        What is coming in the next 10 years? 25:24        What is out there that will get in the way of innovation? 26:54        What advice would you give to residents? 28:35        What advice would you give to entrepreneurs? 30:16        What story can you share about one historical figure in ophthalmology? 31:59        Wrap up and a preview of episode 13, guest David Endicot, Alcon CEO 35:14        Feedback, questions and guest suggestions at eyeluminaries@healio.com 36:29        Thanks for listening 36:53 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Richard L. Lindstrom, MD, is the founder and an Attending Surgeon at Minnesota Eye Consultants and an Adjunct Professor Emeritus at the University of Minnesota, Department of Ophthalmology. He is a board-certified Ophthalmologist and an internationally recognized leader in corneal, cataract, refractive and laser surgery. We'd love to hear from you! Send your comments/questions to eyeluminaries@healio.com. Follow John Hovanesian on Twitter @DrHovanesian. Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Lindstrom reports consulting with AcuFocus, Alcon, Allergan, Bausch + Lomb, Combangio, CorneaGen, Equinox, Eyevance/Santen, Flying L Partners, Harrow Health, J&J Vision, Lensar, Lentechs, MDbackline, Novartis, Orasis, Schroeder Vision Life Sciences, Sun, Surface, Versant Ventures, Visionary Ventures and Zeiss; holds stocks with Acquea, AcuFocus, Combangio, CorneaGen, Equinox, Flying L Investments, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Orasis, Sight4All, Surface, TearClear, TearLab, TherOptix, Unifeye Vision Partners and Visionary Ventures; board chairman of Surface; sits on the board of Acquea, AcuFocus, Combangio, CorneaGen, Equinox, ForSight, Harrow Health, Lensar, Lentechs, MDbackline, Ocular Therapeutix, Sight4All, TearLab, TherOptix and Unifeye Vision Partners; board observer of TearClear; receives compensation from Ocular Therapeutix; member of the investment committee of Flying L Investments and Visionary Ventures; and a medical advisory board member of Acquea, Foresight, Harrow Health, Ocular Therapeutix, Sight4All, TearClear and TearLab.

In this episode of Medsider Radio, we sat down with Jim Biggins, Founder and CEO of Access Vascular.Before starting the company, Jim developed innovative products for companies like Boston Scientific, Ocular Therapeutix, and Medtronic. He then spent 18 months shadowing clinicians in real-life medical settings, which led to the creation of Access Vascular's novel biomaterial for vascular access devices aimed at reducing common patient complications.In this conversation, Jim shares the importance of hearing directly from clinicians in the field, how to plan out a clinical research strategy, and the benefit of questioning assumptions when it comes to commercialization.Before we jump into the conversation, I wanted to mention a few things:If you're into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You'll get access to gated articles, and lots of other interesting healthcare content.Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.In addition to the entire back catalog of Medsider interviews over the past decade, premium members get a copy of every volume of Medsider Mentors sent to their door at no additional cost. If you're interested, go to medsider.com/subscribe to learn more.Lastly, here's the link to the full interview with Jim if you'd rather read it instead.

Now a seasoned medtech entrepreneur and leader, Amar Sawhney first became interested in the industry starting in graduate school. He was studying chemical engineering and developing biodegradable polymers for adhesion prevention and hydrogels for light-activated polymerization within the body. He and his advisor were then approached by Mayfield Fund to spin out the technology into the startup Focal. Amar was fortunate to learn a lot from then CEO Mark Levin, including some hard lessons that drove him and Fred Khosravi to found Incept, an IP holding company for creating operating companies based on field of use. As CEO/Founder of Confluent Surgical, AccessClosure, Augmenix, Ocular Therapeutix, and now Instylla, Amar learned how to transition from scientist to executive and is truly a medtech influencer. In this interview with host Geoff Pardo, Amar shares many of the valuable lessons he's learned founding and managing various startups, including how to find the right application for a technology, when a platform solution really makes sense, how to effectively lead and build successful teams, the value of a diverse workforce, and tips for overcoming the funding gap for early-stage companies, plus his candid thoughts on the differences in funding/entrepreneurship between the East and West coasts.Amarpreet (Amar) Sawhney, Ph.D., is the Founder, Chief Executive Officer and Chairman of the Board of Directors of Instylla. He is also the CEO of Pramand LLC, and Rejoni, Inc. Prior to this Dr. Sawhney served as CEO and Chairman of Augmenix (acquired by Boston Scientific) and Ocular Therapeutix (NASDAQ: OCUL). In addition, he is a general partner of Incept, LLC, an intellectual property holding company. Previously, Dr. Sawhney founded Confluent Surgical and served as its President and CEO prior to its acquisition by Covidien plc. He also was a technology founder of Focal, Inc., a biopharmaceutical company acquired by Genzyme Corporation, and a founder of AccessClosure, Inc., acquired by Cardinal Health. Dr. Sawhney's innovations are the subject of over 120 issued and pending patents. He holds M.S. and Ph.D. degrees in chemical engineering from the University of Texas at Austin, as well as a B.Tech. in chemical engineering from the Indian Institute of Technology, Delhi India.

In this episode, Rick Eiswirth, president and CEO of Alimera Sciences, shares the latest on the phase 4 New Day study of Iluvien, as well as his predictions for the future of ophthalmology. Intro :13 In this episode :18 About Rick Eiswirth :23 What’s your background? How did you get into the ophthalmology industry? 0:51 What are the benefits of Iluvien (fluocinolone acetonide intravitreal implant, Alimera Sciences)? Is this an ideal treatment for 2021? 3:36 How do you get retina specialists more onboard with using intravitreal steroids earlier, given anti-VEGFs’ predominance? 6:26 Can you tell us more about the New Day trial? 8:10 Which trial outcome would be considered a success for Iluvien? 11:58 Do you anticipate a cost savings? 13:58 What’s the status of the New Day trial? 15:15 How has COVID changed the industry landscape in ophthalmology? 16:20 Are there any new products in the pipeline? 18:38 Iluvien is approved in other countries for uveitis 20:36 What have you seen from retina specialists; are there longer efficacy rates? 22:10 What do you think is the most important challenge the ophthalmic community will face in the future? 23:17 Thanks for listening 24:36 Rick Eiswirth is president and CEO of Alimera Sciences. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. Disclosures: Eiswirth is president and CEO of Alimera Sciences. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. McCabe reports consultant relationships with Alcon, Allergan, Bausch and Lomb, Dompe, EyePoint Pharmaceuticals, Ivantis, Novartis, Ocular Therapeutix, Omeros, Sight Sciences and Zeiss. She reports research roles with Alcon, Allergan, Bausch and Lomb, EyePoint Pharmaceuticals, Glaukos, Ivantis, Johnson & Johnson, Ocular Therapeutix and Ora. She also reports an investor relationship with Ocular Innovations.

Michael Goldstein MD, MM Chief Medical Officer at Ocular Therapeutix also served as Co-Director, Cornea, External Disease and Cataract Service; Refractive Surgery Service; Uveitis & Immunology Service; Assistant Professor, Tufts University School of Medicine.

In this episode, Cathleen M. McCabe, MD, chief medical officer of Eye Health America, shares her insights and perspectives on intraocular lenses, MIGS, dry eye and more. Intro :14 In this episode :21 About Cathleen M. McCabe, MD :28 What is your favorite intraocular lens implant to use and why? 2:24 What is your favorite minimally invasive glaucoma surgery (MIGS) to use and why? 4:03 What is your favorite dry-eye treatment to use and why? 4:49 What’s your preferred technique for secondary IOLs? 6:29 How has the role of women in ophthalmology changed throughout the years? 8:46 How did you get involved with international work? How has the pandemic affected this? 10:55 Tell us about your mission work. What are you currently involved in? 12:54 What is the most important topic/issue/challenge facing ophthalmology now or in the future? 15:11 Final words from Dr. McCabe 16:46 Cathleen M. McCabe, MD, is chief medical officer of Eye Health America; medical director of The Eye Associates and president of Outpatient Ophthalmic Surgery Society. We’d love to hear from you! Send your comments/questions to Dr. Mali at eyecareinsider@healio.com. Follow us on Twitter @Healio_OSN. To learn more about the Global Education & Research Society of Ophthalmology (or GERSO), visit https://www.gerso.org. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. McCabe reports consultant relationships with Alcon, Allergan, Bausch and Lomb, Dompe, EyePoint Pharmaceuticals, Ivantis, Novartis, Ocular Therapeutix, Omeros, Sight Sciences and Zeiss. She reports research roles with Alcon, Allergan, Bausch and Lomb, EyePoint Pharmaceuticals, Glaukos, Ivantis, Johnson & Johnson, Ocular Therapeutix and Ora. She also reports an investor relationship with Ocular Innovations.

Join White as he discusses the history of cataract surgery and where femtosecond laser-assisted cataract surgery, or FLACS, fits in. He also explains what he believes to be follies of FLACS and why some people continue to use this procedure. Disclaimer :09 Intro :24 Today we’ll talk about femtosecond laser-assisted cataract surgery, or FLACS :36 Financial disclosures :57 The history of cataract surgery and where FLACS fits in 1:21 The lens supplies about 1/3 of the focusing ability of the human eye 3:35 Scheie Eye Institute 5:42 The discovery of poly(methyl methacrylate) 6:14 Extracapsular cataract extraction 7:14 Cataract surgery moves almost entirely to posterior chamber 7:44 The YAG laser 18:40 Phacoemulsification 19:21 All of these procedures were paid for by health insurance 11:41 The Crystalens 17:00 A petition for patients to have the right to pay to upgrade their implant experience 17:37 The era of refractive cataract surgery 19:03 A false timeline 19:32 Comparing things properly, you find a small difference between two surgeries 22:29 The impressive engineering of femtosecond lasers 23:30 Why do people use the femtosecond laser surgery? 24:53 I do a bit of work as a defense expert in malpractice cases 26:42 There are some bright spots here 29:21 Calling out two groups who don’t let patients decide whether they want FLACS 30:48 I have respect for them, but I don’t think there is justification for doing FLACS based on outcomes 36:13 Throwing a bone to the proponents of FLACS 37:14 That’s my take on FLACS 38:56 We’d love to hear from you! Send your comments/questions to Dr. White at ophthalmology@healio.com. Follow us on Twitter @Healio_OSN @DarrellWhite Disclosures: White reports being a consultant to Allergan, Bruder, EyePoint, Eyevance, Kala, Novartis, Ocular Therapeutix, Omeros, Rendia, Sun and Tearlab; speaker for Allergan, Eyevance, Kala, Novartis, Omeros and Sun; and ownership in Ocular Science.

In this episode, White shares the harsh truths about treating perioperative dry eye, including who, when and for how long. Spoiler: Treated dry eye leads to better outcomes. Disclaimer :09 Intro :24 Treating dry eye around the time of cataract surgery and laser refractive surgery :36 This talk will focus on cataract surgery 1:04 Financial disclosures 1:26 The harsh truths about treating the perioperative dry eye 2:07 Harsh truth #1 3:11 Harsh truth #2 4:11 Harsh truth #3 13:25 Harsh truth #4 14:25 Harsh truth #5 17:17 Harsh truth #6 18:11 Take-home message 25:20 We’d love to hear from you! Send your comments/questions to Dr. White at ophthalmology@healio.com. Follow us on Twitter @Healio_OSN @DarrellWhite Disclosures: White reports being a consultant to Allergan, Bruder, EyePoint, Eyevance, Kala, Novartis, Ocular Therapeutix, Omeros, Rendia, Sun and Tearlab; speaker for Allergan, Eyevance, Kala, Novartis, Omeros and Sun; and ownership in Ocular Science.

Hello, and welcome to this episode of 20/20 Money! My guest on today’s show is Dr. Nysha Blender. Nysha joins me on the show to talk about her journey in optometry and how she ended up in a somewhat unconventional role as a medical science liaison with Ocular Therapeutix. On this show we talk briefly about her path in optometry and what caused her to go down this path of becoming an MSL and what it’s meant to her personally, professionally, and clinically. She gives us an idea of “a day in the life of” and what has surprised her most about being in this position as well as how the compensation structure and numbers compare to her traditional clinical roles as an OD. We wrap it up with her answer to my one question I ask every guest. As a reminder, you can get all the information discussed in today’s conversation by visiting our website at integratedpwm.com and clicking on the Learning Center. While there, you can also set up a 15min pre-discovery conversation to learn a little bit more about what it means to work with our firm or check out any number of additional free resources like our eBooks and on-demand webinars. And with that introduction, I hope you enjoy my conversation with Dr. Nysha Blender. Nysha’s LinkedIn profile Ocular Therapeutix ————————————————————————————— Please rate and subscribe to 20/20 Money on these platforms Apple Podcasts Spotify Google Play Stitcher  ————————————————————————————— For past episodes of 20/20 Money with full companion show notes, please check out our episode archive here!

"If you're a CEO, and you're doing things that are repetitive, then you're probably not doing your job." - Antony Mattessich, CEO of Ocular Therapeutix

New CEO Antony Mattessich says Ocular Therapeutix has learned its mistakes after receiving two CRLs from the FDA. With new leadership and a clear vision, the company is ready to push forward as a full-fledged biopharmaceutical company.

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Prior to starting Ocular Therapeutix, Amar Sawhney, already a successful medtech entrepreneur was a bit concerned about the unique challenges posed by the ophthal-mology sector. Today, with the commercial launch of its ReSure Sealant underway and a suc-cessful IPO completed, Sawhney says he’s more than confident in the plan to build OCUL into a significant ophthalmic player.

MassDevice reporter Brad Periello speaks with CEO and founder of NxStage Medical Jeff Burbank, Zoll CEO Richard Packer, ConforMIS CEO Philipp Lang, and Ocular Therapeutix CEO Amar Sawhney about what it takes to keep companies on the cutting edge, as well as their ups and downs as heads of major medtech companies.